Company
Headquarters: Taipei City, Taiwan
Employees: 35
TW$12.49 Billion
TWD as of Jan. 1, 2024
US$407.2 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04 for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V07 glycan-based vaccines and drugs. The company was founded in 2013 and is based in Taipei City, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
CHO Pharma, Inc. has the following listings and related stock indices.
Stock: TWSE: 6586 wb_incandescent